Gilead Sciences (GILD) Receivables - Other (2018 - 2026)

Gilead Sciences has reported Receivables - Other for 9 years, with the latest figure at $589.0 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other rose 93.75% year-over-year to $589.0 million; the trailing twelve-month figure through Mar 2026 stood at $589.0 million (up 93.75% YoY), and the FY2025 full-year result was $629.0 million, up 127.08% from the prior year.
• Receivables - Other for Q1 2026 stood at $589.0 million, down from $629.0 million in the prior quarter.
• The five-year high for Receivables - Other was $695.0 million in Q3 2025, with the low at $117.0 million in Q4 2023.
• Historically, Receivables - Other has averaged $264.0 million across 5 years, with a median of $167.0 million in 2022.
• Annual changes were most pronounced in 2023 — Receivables - Other sank 31.58% — and 2025, when it soared 277.72%.
• Gilead Sciences' Receivables - Other stood at $171.0 million in 2022, then slumped by 31.58% to $117.0 million in 2023, then soared by 136.75% to $277.0 million in 2024, then jumped by 127.08% to $629.0 million in 2025, then slipped by 6.36% to $589.0 million in 2026.
• The last three Receivables - Other figures came in at $589.0 million (Q1 2026), $629.0 million (Q4 2025), and $695.0 million (Q3 2025), per Business Quant data.